MX2018013070A - Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor. - Google Patents
Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.Info
- Publication number
- MX2018013070A MX2018013070A MX2018013070A MX2018013070A MX2018013070A MX 2018013070 A MX2018013070 A MX 2018013070A MX 2018013070 A MX2018013070 A MX 2018013070A MX 2018013070 A MX2018013070 A MX 2018013070A MX 2018013070 A MX2018013070 A MX 2018013070A
- Authority
- MX
- Mexico
- Prior art keywords
- release
- pain
- pharmaceutical combination
- etoricoxib
- tramadol hydrochloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Combinación farmacéutica que comprende: i) una primera formulación de clorhidrato de tramadol de liberación extendida que contiene desde 2.0% a 12.0% p/p de clorhidrato de tramadol, y ii) una segunda formulación de etoricoxib de liberación inmediata que contiene desde 6.0% a 18% p/p de etoricoxib, disolventes o vehículos; proceso de fabricación para preparar 5 la combinación farmacéutica y las formulaciones individuales, donde la combinación se presenta en una dosificación única tal como, cápsulas, comprimidos, comprimidos en bicapa, granulados y sachets. La presente invención proporciona métodos para prevenir y tratar el dolor, tal como el dolor agudo, y el uso de la combinación farmacéutica para la prevención y el tratamiento del dolor, tal como el dolor agudo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2017/058519 WO2019130049A1 (en) | 2017-12-29 | 2017-12-29 | Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018013070A true MX2018013070A (es) | 2019-10-15 |
Family
ID=61024811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013070A MX2018013070A (es) | 2017-12-29 | 2017-12-29 | Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor. |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR114074A1 (es) |
| MX (1) | MX2018013070A (es) |
| UY (1) | UY38043A (es) |
| WO (1) | WO2019130049A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113521292A (zh) * | 2020-04-15 | 2021-10-22 | 江苏恒瑞医药股份有限公司 | 一种cox-2抑制剂和曲马多的复方制剂 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1207994B (it) | 1986-01-03 | 1989-06-01 | Therapicon Srl | Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche. |
| CA2364127A1 (en) | 1999-03-01 | 2000-09-08 | Ortho-Mcneil Pharmaceutical, Inc. | Composition comprising a tramadol material and a selective cox-2 inhibitor drug |
| AU776544B2 (en) | 1999-11-29 | 2004-09-16 | Merck Canada Inc. | Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-(2,3') bipyridinyl |
| PH12001001175B1 (en) | 2000-05-26 | 2006-08-10 | Merck Sharp & Dohme | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis |
| SI1478366T1 (sl) | 2002-02-19 | 2009-06-30 | Adcock Ingram Ltd | Farmacevtske kombinacije meloksikama, kodein fosfata in paracetamola |
| WO2005085199A1 (en) | 2004-01-14 | 2005-09-15 | Cadila Healthcare Limited | Novel polymorphs of etoricoxib |
| KR101367544B1 (ko) | 2005-06-10 | 2014-02-26 | 추가이 세이야쿠 가부시키가이샤 | 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용 |
| AU2005338461A1 (en) | 2005-11-22 | 2007-05-31 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions of telmisartan |
| BRPI0700133A (pt) | 2007-01-29 | 2008-09-16 | Incrementha P D & I Pesquisa D | composição farmacêutica compreendendo tramadol e cetoprofeno em combinação |
| US20080026054A1 (en) | 2007-04-27 | 2008-01-31 | Nectid Inc. | Novel anelgesic combination |
| BRPI0819451A2 (pt) | 2007-11-23 | 2017-10-03 | Protect Pharmaceutical Corp | Composição farmacêutica, método para tratar dor, kit farmacêutico, e, uso de uma composição |
| EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
| CZ2008740A3 (cs) | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
| EP2281558A1 (en) | 2009-08-06 | 2011-02-09 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical compounds of O-Desmethyl-Tramadol and COX-inhibitors |
| PT2488169E (pt) | 2009-10-16 | 2013-04-03 | Esteve Labor Dr | Co-cristais de tramadol e coxibs |
| WO2012004677A1 (en) | 2010-07-05 | 2012-01-12 | Actavis Group Ptc Ehf | Solid state forms of etoricoxib salts |
| EP2601952A1 (en) | 2011-12-07 | 2013-06-12 | Zentiva, k.s. | Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses |
| HUE033525T2 (en) | 2012-08-27 | 2017-12-28 | Cadila Healthcare Ltd | Pharmaceuticals containing Etoricoxib |
| WO2016015776A1 (en) | 2014-07-31 | 2016-02-04 | Krka, D.D., Novo Mesto | Pharmaceutical composition of etoricoxib |
| WO2016036588A1 (en) | 2014-09-03 | 2016-03-10 | Merck Sharp & Dohme Corp. | Pharmaceutical suspensions containing etoricoxib |
| CN104586799A (zh) | 2015-01-07 | 2015-05-06 | 万全万特制药江苏有限公司 | 依托考昔分散片及其制备方法 |
| CN105343002B (zh) | 2015-11-27 | 2019-07-26 | 济南康和医药科技有限公司 | 一种依托考昔口服微乳制剂及其制备方法 |
| US20170312224A1 (en) * | 2016-04-28 | 2017-11-02 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Extended release formulations of flurbiprofen and tramadol |
| MX2016006464A (es) | 2016-05-18 | 2017-11-17 | Laboratorios Liomont S A De C V | Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor. |
-
2017
- 2017-12-29 MX MX2018013070A patent/MX2018013070A/es unknown
- 2017-12-29 WO PCT/IB2017/058519 patent/WO2019130049A1/en active Application Filing
-
2018
- 2018-12-28 AR ARP180103918A patent/AR114074A1/es unknown
- 2018-12-28 UY UY0001038043A patent/UY38043A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR114074A1 (es) | 2020-07-15 |
| UY38043A (es) | 2019-07-31 |
| WO2019130049A1 (en) | 2019-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004431A (es) | Procesos novedosos. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX2017010544A (es) | Metodos y composiciones para tratar la enfermedad del ojo seco y otros trastornos del ojo. | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| MX2019012884A (es) | Terapia de combinacion. | |
| EA201990831A1 (ru) | Смесительная система для получения косметического продукта и косметическая капсула | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| PH12016501357B1 (en) | Pharmaceutical preparation containing pyridylaminoacetic acid compound | |
| SG11201908234WA (en) | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer | |
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| MX2018000546A (es) | Composiciones farmaceuticas que contienen celecoxib y tramadol. | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
| MX2019007213A (es) | Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. | |
| MX2018013070A (es) | Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor. | |
| PH12017501668A1 (en) | Bace1 inhibitors | |
| MX2021000714A (es) | Preparacion medicinal para uso externo. | |
| MX2016006464A (es) | Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor. | |
| WO2017067664A9 (en) | Oxa-diazaspiro compounds having activity against pain | |
| MX2020001217A (es) | Metodos de tratamiento de sintomas de gastroparesia usando velusetrag. | |
| MX2019001210A (es) | Composicion farmaceutica anticancer. | |
| WO2018030881A3 (ko) | 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도 | |
| MX2017009660A (es) | Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor. | |
| MX2023005681A (es) | Composicion farmaceutica para el tratamiento contra el dolor agudo y cronico, que contiene polmacoxib y tramadol. | |
| MX2018003456A (es) | Combinacion farmaceutica en la forma de comprimidos en bicapa que comprende ketorolaco trometamina y tramadol clorhidrato, y su uso para el tratamiento del dolor. |